| Metric | Q1 FY27 | Q4 FY26 | Q1 FY26 |
|---|---|---|---|
| Revenue from operations | 1265.4 | 1323.5 | 1119.7 |
| Other income | 4.9 | 8.1 | 8.6 |
| Total income | 1270.3 | 1331.6 | 1128.3 |
| Profit before exceptional items & tax | 137.7 | 153.0 | 130.3 |
| Exceptional items | 63.2 | -6.4 | -8.4 |
| Profit before tax | 199.6 | 148.1 | 122.0 |
| Net profit | 165.5 | 129.3 | 105.6 |
| Operating margin | 15.7% | 11.1% | 10.8% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | +56.70% |
|---|---|
| Net profit, quarter on quarter | +28.00% |
| Revenue, year on year | +13.00% |
| Operating profit, year on year | +65.60% |
| Operating profit, quarter on quarter | +32.50% |
BSE results filing, NSE: STAR. Figures extracted from the filing.
Strides Pharma Science Ltd: key numbers
- Share price
- ₹1,184.90
- Market cap
- ₹10,922 Cr
- Revenue (annual)
- ₹4,859 Cr
- Net profit (annual)
- ₹556.2 Cr
- P/E (TTM)
- 17.8×Sector 50.4×
- Promoter holding
- 27.91%+0.00% QoQ
- FII holding
- 28.40%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Strides Pharma Science Ltd
All →Strides Pharma Science Business Update
Strides Pharma Science received a Form 483 with three observations following a routine USFDA inspection at its Alathur formulations facility. The company will respond within stipulated timelines.
Strides Pharma Science Earnings Call Transcript: Key Takeaways
Strides Pharma Science reported Q1 FY27 results with 13% YoY revenue growth and EBITDA margins maintained at 18.2%. Strategy focuses on Ex-US growth and US portfolio diversification.
- Call
- Guides 32% growth
Strides Pharma Science Investor Presentation: Key Takeaways
Strides Q1FY27 revenue grew 13% YoY to ₹12,654m, led by a 17% surge in Ex-US markets. Operational PAT stood at ₹1,231m.
Strides Pharma Science Earnings Call: Key Takeaways
Strides Pharma reported its highest ever EBITDA and operational PAT for FY26, driven by significant geographical diversification and a structural shift toward non-U.S. markets.
Strides Pharma Science Earnings Call: Key Takeaways
Strides delivered strong FY26 performance with Revenue at ₹48,587m, up 6.4%, and Operational PAT at ₹5,181m, growing 50% YoY driven by Ex-US market efficiency.
Strides Pharma Science Q4 FY26 Results: Net Profit ₹129.3 Cr, Up 51.1% YoY
Strides Pharma Science Ltd reported revenue from operations of ₹1,324 Cr (+11.2% YoY) and net profit of ₹129.3 Cr (+51.1% YoY) for Q4 FY26.
- Key figure
- Net profit ₹129.3 Cr · +51.1% YoY